Correction: Boron neutron capture therapy prolongs survival in a rat model of multifocal brain metastases - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Correction: Prolonged Survival Observed with Boron Neutron Capture Therapy in a Rat Model of Multifocal Brain Metastases

  • By

  • Rina Shidoh-Kazuki

  • Yoshiki Fujikawa

  • Shinji Kawabata

  • Kohei Tsujino

  • Hironori Yamada

  • Fugen Takagi

  • Hideki Kashiwagi

  • Ryo Hiramatsu

  • Naosuke Nonoguchi

  • Toshihiro Takami

  • Naonori Hu

  • Takushi Takata

  • Hiroki Tanaka

  • Minoru Suzuki

  • Masahiko Wanibuchi

  • June 4, 2026

Share

Clinical Scorecard: Correction: Prolonged Survival Observed with Boron Neutron Capture Therapy in a Rat Model of Multifocal Brain Metastases

At a Glance

CategoryDetail
Condition
Key MechanismsBoron Neutron Capture Therapy (as per source)
Target PopulationRat model (as per source)
Care Setting

Key Highlights

  • Correction of formula in experimental design section

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

        Risks

          Patient & Prescribing Data

          Boron Neutron Capture Therapy was studied in a rat model.

          Clinical Best Practices

            Related Resources & Content

            Original Source(s)

            Correction: Boron neutron capture therapy prolongs survival in a rat model of multifocal brain metastases

            • by Rina Shidoh-Kazuki, Yoshiki Fujikawa, Shinji Kawabata, Kohei Tsujino, Hironori Yamada, Fugen Takagi, Hideki Kashiwagi, Ryo Hiramatsu, Naosuke Nonoguchi, Toshihiro Takami, Naonori Hu, Takushi Takata, Hiroki Tanaka, Minoru Suzuki, Masahiko Wanibuchi

            • June 4, 2026

            Related Content

            Beyond classical boundaries: rethinking ICU access in acute leukemia

            A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here

            Pancreatic adenocarcinoma, the most common form of pancreatic cancer, accounts for roughly 90 to 95 percent of cases. It's notoriously difficult to catch early, because symptoms often don't appear until the disease has already spread

            • by

            • September 24, 2026

            • 11 min
            Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy